Suppr超能文献

新型博来霉素衍生物NK 631治疗口腔癌的临床效果(作者译)

[Clinical effects of NK 631, a new bleomycin derivative, in treatment of oral cancer (author's transl)].

作者信息

Kajiyama M, Dohjyo M, Ohno A, Nagasaka K, Yamaguma M, Okabe T, Terasaka S

出版信息

Jpn J Antibiot. 1979 Jan;32(1):129-37.

PMID:84883
Abstract

We used only NK 631, a new bleomycin derivative, for 10 cases of primary oral cancer, and obtained following results. (1) Anti-cancer effects were immediate and as follow: remarkably good in 1 case, efficacious in 8 cases, and none in 1 case. (2) In clinical examination, peripheral blood, function of kidney, liver, etc. were normal. But attention must be payed to blood gas. (3) Loss of hair, stomatitis and exanthema were noticed as side effects more clearly than regular bleomycin, but no fever. As the result of the above, NK 631 is better than regular bleomycin in anti-cancer effect and activity, but more attention should be payed to the side effect.

摘要

我们仅对10例原发性口腔癌患者使用了一种新的博来霉素衍生物NK 631,并获得了以下结果。(1)抗癌效果立竿见影,具体如下:1例效果显著良好,8例有效,1例无效。(2)在临床检查中,外周血、肾脏、肝脏等功能均正常。但必须注意血气情况。(3)与常规博来霉素相比,脱发、口腔炎和皮疹等副作用更为明显,但未出现发热症状。综上所述,NK 631在抗癌效果和活性方面优于常规博来霉素,但应更加关注其副作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验